Angel Guzmán-Pérez

Scorpion Therapeutics (United States) — United States

Chemistry · Physical Sciences

32h-index5.8kcitations78works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asymmetric Synthesis and Catalysis(10), Computational Drug Discovery Methods(10), Pancreatic function and diabetes(8), Machine Learning in Materials Science(8), Diabetes Treatment and Management(7)

Publications78 total

RECENT ADVANCES IN SELECTIVELY TARGETING PI3Kα
Medicinal chemistry reviews·2024
Discovery of 6-Oxo-4-phenyl-hexanoic acid derivatives as RORγt inverse agonists showing favorable ADME profile
Bioorganic & Medicinal Chemistry Letters·2021· 3 citedOpen Access
Discovery of [1,2,4]Triazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists
ACS Medicinal Chemistry Letters·2020· 23 citedOpen Access
Correction to Analyzing Learned Molecular Representations for Property Prediction
Journal of Chemical Information and Modeling·2019· 36 citedOpen Access
CCDC 1947050: Experimental Crystal Structure Determination
The Cambridge Structural Database·2019Open Access
Analyzing Learned Molecular Representations for Property Prediction
2019· 5 citedOpen Access
Analyzing Learned Molecular Representations for Property Prediction
Journal of Chemical Information and Modeling·2019· 1.6k citedOpen Access
Are Learned Molecular Representations Ready for Prime Time?
2019· 15 citedOpen Access
Are Learned Molecular Representations Ready for Prime Time?
2019· 27 citedOpen Access
Analyzing Learned Molecular Representations for Property Prediction
2019· 113 citedOpen Access
Analyzing Learned Molecular Representations for Property Prediction
arXiv (Cornell University)·2019· 204 citedOpen Access
Increased building block access through collaboration
Drug Discovery Today·2018· 10 cited
Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors
Bioorganic & Medicinal Chemistry Letters·2017· 8 citedOpen Access
The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement
Bioorganic & Medicinal Chemistry Letters·2017· 20 citedOpen Access
Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators
European Journal of Medicinal Chemistry·2017· 11 citedOpen Access
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity
Journal of Medicinal Chemistry·2017· 66 citedOpen Access
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities
Journal of Medicinal Chemistry·2017· 49 citedOpen Access
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors
Journal of Medicinal Chemistry·2016· 38 citedOpen Access
Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na<sub>V</sub>1.7 inhibitors
MedChemComm·2016· 6 citedOpen Access
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective Na<sub>V</sub>1.7 Inhibitors
Journal of Medicinal Chemistry·2016· 42 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Hua Gao(10), Gary E. Aspnes(10), E. J. Corey(9), John Litchfield(9), Meihua Tu(9), Hakan Günaydin(9), Jeffrey A. Pfefferkorn(8), Jianwei Bian(8), Erin F. DiMauro(8), Mary T. Didiuk(8), Christian Perreault(8), Kevin J. Filipski(7), Karen Atkinson(7), Howard Bregman(7), Liyue Huang(6), Kevin Yang(5), Wengong Jin(5), Connor W. Coley(5), Miriam Mathea(5), Volker Settels(5)